Expression and significance of tetraspanin in gastric cancer

Abstract

Nie Xiaofei, Qiu Zhenkang, Liu Ning, Qi Weiwei, Ding Aiping, Qiu Wensheng. Expression and significance of tetraspanin in gastric cancer[J]. Journal of International Oncology, 2017, 44(7): 537-540.

［1］ Charrin S, Jouannet S, Boucheix C, et al. Tetraspanins at a glance［J］. J Cell Sci, 2014, 127(Pt 17): 3641-3648. DOI: 10.1242/jcs.154906. ［2］ Shiwu WU, Lan Y, Wenqing S, et al. Expression and clinical significance of CD82/KAI1 and Ecadherin in nonsmall cell lung cancer［J］. Arch Iran Med, 2012, 15(11): 707-712. DOI: 0121511/AIM.0012. ［3］ Zhang W, Zhao CG, Sun HY, et al. Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma［J］. Gut Liver, 2014, 8(5): 536-542. DOI: 10.5009/gnl13331. ［4］ Knoener M, Krech T, Puls F, et al. Limited value of KAI1/CD82 protein expression as a prognostic marker in human gastric cancer［J］. Dis Markers, 2012, 32(6): 337-342. DOI: 10.3233/DMA-2012-0896. ［5］周蕾, 武世伍, 俞岚, 等. 胃腺癌组织KAI1的表达及与血管、淋巴管生成的关系［J］. 四川大学学报: 医学版, 2014, 45(1): 43-48. DOI: 10.13464/j.scuxbyxb.2014.01.010. ［6］ Zheng HC, Wang MC, Li JY, et al. Expression of maspin and kai1 and their clinicopathological significance in carcinogenesis and progression of gastric cancer［J］. Chin Med Sci J, 2004, 19(3): 193-198. ［7］ Huan J, Gao Y, Xu J, et al. Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma［J］. Int J Clin Exp Pathol, 2015, 8(3): 3054-3061. ［8］ Kischel P, Bellahcene A, Deux B, et al. Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases［J］. Anticancer Res, 2012, 32(12): 5211-5220. ［9］ Chen Z, Gu S, Trojanowicz B, et al. Downregulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma［J］. World J Surg Oncol, 2011, 9: 43. DOI: 10.1186/1477-7819-9-43. ［10］张徐宁, 季润元, 史恩溢, 等. 胃癌组织中MRP1/CD9、KAI1/CD82和ME491/CD63的表达及意义［J］. 广东医学, 2013, 34(21): 3264-3266. ［11］ Hori H, Yano S, Koufuji K, et al. CD9 expression in gastric cancer and its significance［J］. J Surg Res, 2004, 117(2): 208-215. DOI: 10.1016/j.jss.2004.01.014. ［12］ Soyuer S, Soyuer I, Unal D, et al. Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy［J］. Pathol Res Pract, 2010, 206(9): 607-610. DOI: 10.1016/j.prp.2010.04.004. ［13］ Murayama Y, Oritani K, Tsutsui S. Novel CD9targeted therapies in gastric cancer［J］. World J Gastroenterol, 2015, 21(11): 3206-3213. DOI: 10.3748/wjg.v21.i11.3206. ［14］ Qin Y, Mohandessi S, Gordon L. Regulation of FAK activity by tetraspan proteins: potential clinical implications in cancer［J］. Crit Rev Oncog, 2015, 20(5-6): 391-405. DOI: 10.1615/CritRevOncog.v20.i5-6.110. ［15］ Schenk GJ, Dijkstra S, van het Hof AJ, et al. Roles for HBEGF and CD9 in multiple sclerosis［J］. Glia, 2013, 61(11): 1890-1905. DOI: 10.1002/glia.22565. ［16］ Wang HX, Hemler ME. Novel impact of EWI2, CD9, and CD81 on TGFβ signaling in melanoma［J］. Mol Cell Oncol, 2015, 2(1): e1030536. DOI: 10.1080/23723556.2015.1030536. ［17］ Kwon MJ, Seo J, Kim YJ, et al. Prognostic significance of CD151 overexpression innonsmall cell lung cancer［J］. Lung Cancer, 2013, 81(1): 109-116. DOI: 10.1016/j.lungcan.2013.03.014. ［18］ Suzuki S, Miyazaki T, Tanaka N, et al. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness［J］. Ann Surg Oncol, 2011, 18(3): 888-893. DOI: 10.1245/s10434-010-1387-3. ［19］ Kwon MJ, Park S, Choi JY, et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer［J］. Br J Cancer, 2012, 106(5): 923-930. DOI: 10.1038/bjc.2012.11. ［20］ Yang YM, Zhang ZW, Liu QM, et al. Overexpression of CD151 predicts prognosis in patients with resected gastric cancer［J］. PLoS One, 2013, 8(3): e58990. DOI: 10.1371/journal.pone.0058990. ［21］ Kang BW, Lee D, Chung HY, et al. Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer［J］. J Cancer Res Clin Oncol, 2013, 139(11): 1835-1843. DOI: 10.1007/s00432-013-1503-4. ［22］ Ha SY, Do IG, Lee J, et al. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer［J］. Ann Surg Oncol, 2014, 21(4): 1099-1106. DOI: 10.1245/s10434013-3339-1. ［23］ Zhu H, Wu Y, Zheng W, et al. CO029 is overexpressed in gastric cancer and mediates the effects of EGF on gastric cancer cell proliferation and invasion［J］. Int J Mol Med, 2015, 35(3): 798802. DOI: 10.3892/ijmm.2015.2069. ［24］ Wei L, Li Y, Suo Z. TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway［J］. Int J Clin Exp Med, 2015, 8(6): 8599-8607. ［25］ Anami K, Oue N, Noguchi T, et al. TSPAN8, identified by Escherichia coli ampicillin secretion trap, is associated with cell growth and invasion in gastric cancer［J］. Gastric Cancer, 2016, 19(2): 370-380. DOI: 10.1007/s10120-015-0478-z. ［26］ Chen L, Li X, Wang GL, et al. Clinicopathological significance of overexpression of TSPAN1, KI67 and CD34 in gastric carcinoma［J］. Tumori, 2008, 94(4): 531-538. ［27］ Lu Z, Luo T, Nie M, et al. TSPAN1 functions as an oncogene in gastric cancer and is downregulated by miR573［J］. FEBS Lett, 2015, 589(15): 1988-1994. DOI: 10.1016/j.febslet.2015.05.044. ［28］ He P, Wang S, Zhang X, et al. Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer［J］. Oncotarget, 2016, 7(26): 40160-40173. DOI: 10.18632/oncotarget.9514. ［29］ Yoo TH, Ryu BK, Lee MG, et al. CD81 is a candidate tumor suppressor gene in human gastric cancer［J］. Cell Oncol, 2013, 36(2): 141-153. DOI: 10.1007/s13402-012-0119-z.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[11]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[12]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[13]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.

Expression and significance of tetraspanin in gastric cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments